05/20/2002 By Anne MacLennan
Adjuvant methotrexate treatment does not appear to reduce disease activity in patients with newly diagnosed giant cell arteritis, a multicentre international trial has found.
Findings from a study conducted with 98 patients at 16 centres of the International Network for the Study of Systemic Vasculitides do not support the adjunctive use of methotrexate (MTX) to control disease activity or to decrease the cumulative dose and toxicity of cumulative corticosteroid (CS) in these patients, researchers report.
Gary S. Hoffman from the Cleveland Clinic Foundation, Cleveland, Ohio, United States, and colleagues from various international institutions enrolled patients with unequivocal giant cell arteritis (GCA) for their randomised, double blind study. Their objective was to determine if MTX reduces GCA relapses and CS requirements and diminishes disease- and treatment-related morbidity. The patients, who were enrolled over four years, were initially treated with prednisone 1 mg/kg/day, up to a maximum of 60 mg every day, plus either placebo or 0.15 mg/kg/week MTX, increased to 0.25 mg/kg/week for a maximum weekly dosage of 15 mg. Median dosage of MTX was 15 mg/week.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!